News

Study finds anti-NGF drug effective for hip OA


 

FROM ARTHRITIS & RHEUMATISM

The rate of total hip replacements was similar in the treatment and placebo groups, with a total of eight patients who had a total hip replacement (three in the placebo group, two each in the 2.5-mg and 5-mg groups, and one in the 10-mg group). These included two patients on tanezumab who had osteonecrosis thought to be related to tanezumab. The authors pointed out that an outside adjudication committee, however, did not confirm osteonecrosis in either patient, and concluded that the reasons for joint replacements in the eight patients were inflammatory arthropathy, end-stage OA, rapidly progressive OA, or worsening OA.

Dr. Altman said that he has consulted with Abbott and its now discontinued program on anti-NGF drugs.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Loss of BMD linked to knee OA progression
MDedge Internal Medicine
Mycophenolate boosted vital capacity in connective tissue ILD
MDedge Internal Medicine
Follow mild, inactive lupus patients every 3-4 months
MDedge Internal Medicine
Platelet-rich plasma improved tennis elbow pain
MDedge Internal Medicine
Rheumatoid arthritis associated with higher post-MI death risk
MDedge Internal Medicine
All glucocorticoids linked to increased risk of VTE
MDedge Internal Medicine
RA patients have increased aortic inflammation
MDedge Internal Medicine
Obesity interferes with TNF-alpha inhibitors in psoriatic arthritis
MDedge Internal Medicine
Exceeding 10 mg/day prednisone increased CV events in lupus
MDedge Internal Medicine
'Mobility shoes' potentially benefit knee OA
MDedge Internal Medicine

Related Articles